Your browser is no longer supported. Please, upgrade your browser.
CTMX CytomX Therapeutics, Inc. weekly Stock Chart
CTMX [NASD]
CytomX Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own0.20% Shs Outstand46.20M Perf Week15.99%
Market Cap345.11M Forward P/E- EPS next Y-2.65 Insider Trans0.00% Shs Float41.18M Perf Month3.32%
Income-102.20M PEG- EPS next Q-0.56 Inst Own82.60% Short Float3.46% Perf Quarter-13.09%
Sales57.50M P/S6.00 EPS this Y-11.10% Inst Trans0.40% Short Ratio3.14 Perf Half Y0.95%
Book/sh1.12 P/B6.67 EPS next Y-9.10% ROA-26.20% Target Price14.82 Perf Year-31.78%
Cash/sh6.41 P/C1.17 EPS next 5Y-0.90% ROE-114.50% 52W Range3.60 - 12.63 Perf YTD-10.11%
Dividend- P/FCF- EPS past 5Y-17.70% ROI-216.20% 52W High-40.86% Beta0.74
Dividend %- Quick Ratio3.50 Sales past 5Y62.50% Gross Margin- 52W Low107.79% ATR0.75
Employees158 Current Ratio3.50 Sales Q/Q-27.80% Oper. Margin- RSI (14)59.29 Volatility9.91% 13.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.10% Profit Margin- Rel Volume0.90 Prev Close7.40
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 AMC Payout- Avg Volume453.40K Price7.47
Recom1.90 SMA2026.87% SMA5010.48% SMA200-6.62% Volume408,332 Change0.95%
Mar-24-20Upgrade Wedbush Neutral → Outperform
Mar-04-20Initiated Barclays Equal Weight $7
Nov-20-19Initiated Guggenheim Buy
Nov-11-19Downgrade Wedbush Outperform → Neutral $25 → $8
Jun-13-19Initiated Mizuho Buy
May-14-19Initiated Cantor Fitzgerald Overweight $21
Mar-11-19Initiated Barclays Overweight $16
Nov-26-18Initiated Piper Jaffray Overweight $22
Oct-15-18Initiated Goldman Neutral $21
Sep-13-18Initiated H.C. Wainwright Buy $32
Jun-01-18Initiated SunTrust Buy $38
Jan-05-18Initiated Citigroup Buy $40
Sep-08-17Initiated Wedbush Outperform $26
Mar-27-17Initiated H.C. Wainwright Buy $24
Mar-02-17Initiated Instinet Buy $21
Jan-03-17Downgrade Oppenheimer Outperform → Perform
Nov-02-15Initiated Oppenheimer Outperform $17
Nov-02-15Initiated Jefferies Buy $19
Nov-02-15Initiated BofA/Merrill Buy
Mar-31-20 08:26AM  The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions Benzinga +14.48%
Mar-30-20 04:15PM  CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline GlobeNewswire +5.51%
Mar-25-20 04:02PM  CytomX Therapeutics Announces New Employment Inducement Grant GlobeNewswire
10:13AM  CytomX & Astellas Collaborate to Develop Novel Cancer Therapy Zacks
Mar-24-20 05:35PM  Peninsula biotech scores $80M upfront in potential $1.6 billion cancer drug deal American City Business Journals +32.45%
08:20AM  The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test Benzinga
Mar-23-20 08:00PM  CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer GlobeNewswire
04:02PM  CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER GlobeNewswire
Mar-16-20 04:23PM  CytomX Therapeutics Announces New Employment Inducement Grant GlobeNewswire -30.17%
Mar-11-20 03:39PM  Edited Transcript of CTMX earnings conference call or presentation 27-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -9.13%
Feb-29-20 08:34AM  CytomX Therapeutics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
Feb-27-20 05:45PM  CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:28PM  CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update GlobeNewswire
12:00PM  CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Feb-25-20 08:00AM  CytomX Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference GlobeNewswire
Feb-24-20 08:00AM  Bristol-Myers Squibb Advances CytomX Therapeutics Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial GlobeNewswire
Feb-20-20 08:00AM  CytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results GlobeNewswire
Feb-19-20 12:31PM  Will CytomX Therapeutics (CTMX) Report Negative Q4 Earnings? What You Should Know Zacks
Feb-07-20 04:02PM  CytomX Therapeutics Announces New Employment Inducement Grant GlobeNewswire -9.15%
Feb-05-20 11:52AM  Steven Cohen Renews His Interest in Verastem GuruFocus.com
Feb-03-20 08:00AM  CytomX Therapeutics Appoints Alison L. Hannah, M.D. as Chief Medical Officer GlobeNewswire
Jan-17-20 04:10PM  CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Dec-31-19 09:07AM  The CytomX Therapeutics (NASDAQ:CTMX) Share Price Is Down 45% So Some Shareholders Are Getting Worried Simply Wall St.
Dec-19-19 08:03AM  CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook GlobeNewswire +8.98%
Dec-17-19 04:03PM  CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Dec-09-19 01:10PM  Hedge Funds Have Never Been More Bullish On CytomX Therapeutics, Inc. (CTMX) Insider Monkey
Dec-06-19 04:06PM  CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Nov-26-19 09:56PM  Edited Transcript of CTMX earnings conference call or presentation 7-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-11-19 11:55AM  Wedbush Downgrades CytomX Due To Lack Of Clarity On Development Paths Benzinga -6.05%
08:00AM  CytomX Therapeutics to Present at Upcoming Healthcare Conferences GlobeNewswire
Nov-07-19 04:09PM  CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Oct-31-19 10:34AM  Will CytomX Therapeutics (CTMX) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-30-19 05:23PM  CytomX Therapeutics, Inc. (CTMX) Is Burning These Hedge Funds Insider Monkey
Oct-29-19 04:04PM  CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma GlobeNewswire -5.52%
Oct-24-19 08:00AM  CytomX Therapeutics to Announce Third Quarter 2019 Financial Results GlobeNewswire -6.91%
Oct-18-19 04:05PM  CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire -5.62%
Oct-14-19 08:00AM  CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer GlobeNewswire
Sep-21-19 10:20AM  Will CytomX Therapeutics (NASDAQ:CTMX) Spend Its Cash Wisely? Simply Wall St.
Aug-28-19 08:00AM  CytomX Therapeutics to Present at Upcoming Healthcare Conferences GlobeNewswire
Aug-16-19 02:22PM  Did CytomX Therapeutics, Inc. (NASDAQ:CTMX) Insiders Buy Up More Shares? Simply Wall St.
12:00AM  Edited Transcript of CTMX earnings conference call or presentation 7-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-19 12:37AM  CytomX Therapeutics, Inc. (CTMX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 07:05PM  CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:10PM  CytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-06-19 08:00AM  CytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire +8.35%
Jul-31-19 10:36AM  Earnings Preview: CytomX Therapeutics (CTMX) Q2 Earnings Expected to Decline Zacks
Jul-30-19 08:00AM  CytomX Therapeutics to Announce Second Quarter 2019 Financial Results GlobeNewswire
Jul-10-19 11:57AM  Analyst: CytomX Therapeutics Validated By AbbVie Decision Benzinga
Jul-09-19 08:00AM  CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration GlobeNewswire +9.32%
Jun-29-19 08:09AM  Did You Manage To Avoid CytomX Therapeutics's (NASDAQ:CTMX) Painful 51% Share Price Drop? Simply Wall St.
Jun-19-19 03:30PM  Heres What Hedge Funds Think About CytomX Therapeutics, Inc. (CTMX) Insider Monkey
Jun-01-19 09:00AM  CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting GlobeNewswire
May-28-19 08:00AM  CytomX Therapeutics to Present at Upcoming Healthcare Conferences GlobeNewswire
May-22-19 12:57PM  Edited Transcript of CTMX earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-15-19 05:20PM  CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting GlobeNewswire
May-13-19 01:00PM  CytomX Therapeutics, Inc. (CTMX) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 07:32PM  Were Hedge Funds Right About Dumping CytomX Therapeutics, Inc. (CTMX)? Insider Monkey
05:35PM  CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:32PM  CytomX Therapeutics: 1Q Earnings Snapshot Associated Press
04:10PM  CytomX Therapeutics Announces First Quarter 2019 Financial Results GlobeNewswire
May-08-19 08:29AM  Edited Transcript of CTMX earnings conference call or presentation 6-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
May-07-19 08:00AM  CytomX Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
May-02-19 08:00AM  CytomX Therapeutics to Announce First Quarter 2019 Financial Results GlobeNewswire +5.78%
May-01-19 10:33AM  Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-23-19 06:00AM  Long-Term "GameChangers" in Biotech MoneyShow +5.04%
Apr-22-19 04:05PM  CytomX Therapeutics Appoints Elaine V. Jones, Ph.D., to Board of Directors GlobeNewswire
Apr-11-19 01:19PM  What Kind Of Investor Owns Most Of CytomX Therapeutics, Inc. (NASDAQ:CTMX)? Simply Wall St.
Apr-05-19 03:04PM  Consider These 3 Falling Knives GuruFocus.com
Apr-02-19 08:00AM  AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166 GlobeNewswire
Mar-26-19 07:36AM  The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs Benzinga
Mar-25-19 04:05PM  CytomX Therapeutics Announces Transition of Chief Financial Officer GlobeNewswire
Mar-06-19 08:25AM  Have Insiders Been Buying CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares? Simply Wall St. -8.43%
Mar-05-19 04:05PM  CytomX to Present at Upcoming Healthcare Conferences GlobeNewswire
Mar-03-19 02:30AM  Edited Transcript of CTMX earnings conference call or presentation 27-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-27-19 05:11PM  CytomX Therapeutics Announces Presentations at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
04:08PM  CytomX Therapeutics Announces Full-Year 2018 Financial Results GlobeNewswire
Feb-26-19 05:28PM  Big Pharma trims projects and a potential $1 billion in payments from collaboration with small Peninsula biotech American City Business Journals -31.47%
07:30AM  CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody Therapeutic Platform GlobeNewswire
Feb-20-19 10:31AM  Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for Zacks
07:25AM  Analysis: Positioning to Benefit within Jacobs Engineering Group, Ares Capital, CytomX Therapeutics, FuelCell Energy, Timken, and Farmland Partners Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-14-19 04:02PM  CytomX Therapeutics to Announce Full-Year 2018 Financial Results and Host Webcast Conference Call GlobeNewswire
Feb-05-19 08:00AM  CytomX Therapeutics Announces Senior Management Appointments GlobeNewswire
Jan-30-19 08:00AM  CytomX Therapeutics to Host Research and Development Day on February 26, 2019 GlobeNewswire
Jan-22-19 11:14AM  Are CytomX Therapeutics, Inc.s (NASDAQ:CTMX) Interest Costs Too High? Simply Wall St.
Jan-16-19 09:03AM  CytomX Therapeutics Shares March Higher, Can It Continue? Zacks
Jan-07-19 08:00AM  CytomX Therapeutics Announces Technology Acquisition From Agensys, Inc., an Affiliate of Astellas Pharma Inc. GlobeNewswire
Dec-20-18 08:00AM  CytomX Therapeutics Announces Changes to its Board of Directors GlobeNewswire
Dec-17-18 01:44AM  Is CytomX Therapeutics, Inc. (CTMX) A Good Stock To Buy? Insider Monkey
Dec-14-18 02:28PM  Goldman Sachs Takes Action on Pharma Stocks GuruFocus.com
Nov-27-18 08:10AM  Consolidated Research: 2018 Summary Expectations for CarGurus, ARMOUR Residential REIT, Braskem S.A, HCI Group, Kimball Electronics, and CytomX Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-20-18 02:45PM  Should You Worry About CytomX Therapeutics Incs (NASDAQ:CTMX) CEO Pay? Simply Wall St.
Nov-09-18 08:00AM  CytomX Therapeutics Presents CX-072 Clinical Translational Data at 2018 SITC Annual Meeting GlobeNewswire -8.26%
Nov-07-18 08:00AM  CytomX to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire +25.10%
Nov-06-18 06:00PM  CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates Zacks -8.80%
04:58PM  CytomX Therapeutics: 3Q Earnings Snapshot Associated Press
04:05PM  CytomX Therapeutics Announces Third Quarter 2018 Financial Results GlobeNewswire
08:13AM  CytomX Therapeutics Announces CX-072 Clinical Presentations at 2018 SITC Annual Meeting GlobeNewswire
Oct-30-18 04:03PM  CytomX Therapeutics to Announce Third Quarter 2018 Financial Results GlobeNewswire
Oct-22-18 06:45AM  CytomX Therapeutics Presents Clinical Data from Probody Platform and CX-072 at 2018 ESMO Annual Meeting GlobeNewswire
Oct-12-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX Therapeutics, Extreme Networks, Heron Therapeutics, and Alteryx New Research Emphasizes Economic Growth GlobeNewswire
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.